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The Pharmacological Treatment of Ischemic Stroke goes beyond tPa: 
Edaravone, an Already Commercialized Promise. 
Patophisiology and therapeutic targetsIntroduction
Ischemic stroke is the third leading cause of death in industrialized countries and the most frequent
cause of permanent disability in adult worldwide. As expected, disability involves tremendous
personal and financial cost to the individual, the family and the health care system.



























o To prevent early
recurrent stroke





o To restore circulation






 Protecting ischemic 












Beyond the antioxidant effects…  








Plasma edaravone concentration seems to
disappear without accumulation
Under clinical investigation
LOW rate of side
effects
30mg
When administrated twice a day in 












Illustration adapted from WebMD, (2015). Ischemic Stroke. [online] Available at: http://www.webmd.com/stroke/ischemic-stroke [Accessed 25 Mar. 2015]. 




%20Edaravone. [Accessed 26 Apr. 
2015].
o Edaravone belongs to phenol
compounds
o Lipofhilic
o Low molecular weight
Able to cross the 
blood brain barrier
Illustration adapted from Favaloro B, Allocati N, Graziano V, Di Ilio C, De Laurenzi V. Role of
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When administrated within 72 
hours…. 
Bono Miralles, Bea
Autonomous University of Barcelona – Faculty of Biosciences – Degree in Biomedical Sciences
tPA
edaravone
o Reduced edema 
o Less white matter tissue rate
o Inhibition of tPA-induced hemorrhagic
transformation
o Less blood-brain barrier damage and oxidative
stress 
Edaravone strengthen thrombolysis when administrated
with tpA, thus increasing benefits of early, but not late, tPA
therapy
Safety Tolerability Efficacy Indications
The kind of 








o 3rd leading cause of 
death in industralized
countries
o Huge repercussion on
the individual
o Frequent cause of 
permanent disability in 
adult







o the amount of 
potential therapeutic 
targets is immense.
o many strategies 
proposed
o necessary to promote 






Thanks to the efforts made by some researches, there are some drugs in a very advanced stage likely
to become a reality.
Blood clot stops the
flow of blood to an










Illustration adapted from Neurowiki2013, (2015). Alzheimer’s Disease and Stroke - Neurowiki. 
[online] Available at: http://neurowiki2013.wikidot.com/individual:alzheimers-disease-and-stroke 




Synergy of combined tPA – Edaravone therapy
Europ, why not? 
Objectives
o Make an overview of the main pharmacological treatments for ischemic stroke.
o Provide a general view of the main therapies that are in process of investigation, giving special
attention to those that are likely to hit the market in the near future.
o To focus on edaravone, the only free radical scavenger that has provided clinical evidence for
therapeutic effects on ischemic stroke.
Source:
Data obtained from papers and reviews researched
on PubMed database and specialized literature.
Criteria of selection
Use of key words such as: ischemic stroke,
penumbra, edaravone, pharmacological
treatment.
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